Regeneron chief outranks every other biopharma CEO with $36M in 2013 pay

Regeneron CEO Leonard Schleifer

Last year, little Regeneron ($REGN) gave its top executives a big payday. The company's vision-loss drug Eylea was breaking sales records left and right. Its colon cancer drug, developed with Sanofi ($SNY), had hit the market. And the company's board figured that keeping its key people was worth millions--a total of $140 million, in fact, mostly in stock and option awards.

The company's R&D chief, George Yancopoulos, took more than $80 million of that, but CEO Leonard Schleifer wasn't left out; he netted a $30 million pay package, putting him in first place on FiercePharma's annual list of highest-paid executives.

Now, Schleifer has Yancopoulos beat. In fact, he has almost every biopharma CEO beat.

Schleifer's 2013 pay package amounted to $36.3 million, an increase of 21%.

That makes him the industry's highest-paid chief of the year once again. Tony Coles, who headed up Onyx Pharmaceuticals till Amgen ($AMGN) bought the company last year, walked away with an estimated $63 million in goodbye pay, including severance, bonus, and cash from newly vested options and shares. But among CEOs still on the job, Schleifer is No. 1.


For a reason, look no further than Eylea, which jumped to blockbuster status last year. After an already impressive launch beginning in November 2011, Eylea brought in $1.41 billion in the U.S. for 2013, a year-over-year increase of 70%. The drug is going strong overseas, too, with Bayer racking up about $472 million for the year.

The company's performance has been strong enough to prompt Sanofi ($SNY), its partner on a promising experimental cholesterol drug in addition to Zaltrap, to raise its stake in the company several times over the past year. That cholesterol fighter, alirocumab, is part of a closely watched class of new drugs, and analysts have forecast as much as $3 billion in sales.

Special Reports: The Top 15 Drug Launch Superstars - Eylea | 20 Highest-Paid Biopharma CEOs of 2012 - Leonard 'Len' Schleifer - Regeneron | 10 top drugs in biopharma's late-stage pipeline - Alirocumab, Sanofi and Regeneron

Suggested Articles

Which rollouts might suffer most? Those that treat chronic diseases, require doctors to administer them or face current competition, analysts say.

Novartis and Incyte will put their blockbuster JAK inhibitor into phase 3 clinical trials as a possible treatment for COVID-19, the drugmakers said.

The Cannes Lions canceled its advertising creativity conference for 2020 after media reports that many large ad agencies planned to opt out.